U.S. MARKETS FOR PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY AND CORONARY STENTING PRODUCTS

192 Pages | 33 Exhibits | 2010 Analysis | Forecasts Through 2014

OVERVIEW:
In the United States (U.S.), the single largest cause of death--and also the greatest cause of premature and permanent disability in the labor force--is coronary heart disease (CHD). Nearly 18 million adults age 20 or older in the U.S. suffer from CHD, which is responsible for more than 50% of all cardiovascular events in men and women younger than age 75, and for 1 out of every 6 deaths in the country. The morbidity and mortality rates associated with CHD continue to fuel the demand for percutaneous transluminal coronary angioplasty (PTCA) and coronary stenting products to treat patients who cannot be adequately managed with lifestyle changes or medical therapy.

Together, more than a million PTCA and coronary stenting procedures were performed in the U.S. in 2009, generating approximately $4.2 billion in corresponding product sales. It is expected that during the forecast period covered by this report, sales of PTCA and coronary stenting products will increase at a compound annual rate of 6.6%, reaching an estimated $5.8 billion in the year 2014.

This dynamic, new report from Medtech Insight includes analyses of products, current and forecast markets, competitors, and opportunities for suppliers of PTCA and coronary stenting products to the U.S.

Covered topics in this report include bare-metal and drug-eluting stent systems; conventional and drug-eluting balloon angioplasty procedures; conventional balloon angioplasty catheters; coronary heart disease and population statistics; coronary stenting procedures; drug-eluting balloon angioplasty catheters; guidewires; guiding catheters; inflation devices; introducers/sheaths; stent coatings and surfaces and anti-restenosis agents; stent configurations and materials; technological developments in coronary angioplasty and stenting; and vascular access site closure devices.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY
    i. Percutaneous Transluminal Coronary Angioplasty Devices Market 
    ii. Coronary Stenting Systems Market 
    iii. Methodology 

Exhibit ES-1: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit ES-2: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting Products, Market Forecast, 2009-2014 
Exhibit ES-3: Percutaneous Transluminal Coronary Angioplasty Devices, Market Forecast, 2009-2014 
Exhibit ES-4: Coronary Stents, Market Forecast, 2009-2014 

1. CORONARY HEART DISEASE OVERVIEW 
	1.1 The Heart and Circulatory System 
	1.2 Selected Heart Diseases/Disorders 
        1.2.1 Coronary Heart Disease
            1.2.1.1 Atherosclerosis 
            1.2.1.2 Angina Pectoris
            1.2.1.3 Myocardial Infarction 
        1.2.2 Hypertension 
            1.2.2.1 Systolic and Diastolic Pressures 
            1.2.2.2 Prehypertension 
        1.2.3 Cardiac Dysrhythmia 
            1.2.3.1 Bradycardia 
            1.2.3.2 Sick Sinus Syndrome 
            1.2.3.3 Heart Block 
            1.2.3.4 Atrial Fibrillation 
            1.2.3.5 Tachycardia 
            1.2.3.6 Ventricular Fibrillation 
        1.2.4 Cardiomyopathy 
            1.2.4.1 Dilated Cardiomyopathy
            1.2.4.2 Hypertrophic Cardiomyopathy 
            1.2.4.3 Restrictive Cardiomyopathy 
        1.2.5 Congenital Heart Defects 
            1.2.5.1 Ventricular Septal Defects 
            1.2.5.2 Atrial Septal Defects 
            1.2.5.3 Patent Ductus Arteriosus 
        1.2.6 Heart Failure 
            1.2.6.1 Disease Development 
            1.2.6.2 Ejection Fraction Reduction 
            1.2.6.3 Classification/Staging Systems 

Exhibit 1-1: Cross-Section Diagram of the Heart 
Exhibit 1-2: Cross-Section Diagram of the Heart Valves 
Exhibit 1-3: Statistics for Selected Coronary Heart Disease Risk Factors 
Exhibit 1-4: Standard Angina Pectoris Classification 
Exhibit 1-5: Angina Pectoris, Selected Statistics 
Exhibit 1-6: Myocardial Infarction, Selected Statistics 
Exhibit 1-7: Percentage of Adults Who Have Been Told They Have High Blood Pressure, by State 
Exhibit 1-8: Hypertension, Selected Statistics 
Exhibit 1-9: Cardiac Dysrhythmia, Selected Statistics 
Exhibit 1-10: Cardiomyopathy, Selected Statistics
Exhibit 1-11: Congenital Heart Defects, Selected Statistics 
Exhibit 1-12: Summary, New York Heart Association Heart Failure Classification System
Exhibit 1-13: Summary, American College of Cardiology/American Heart Association Heart Failure Staging System 
Exhibit 1-14: Heart Failure, Selected Statistics 

2. PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY PRODUCTS MARKET 
    2.1 Percutaneous Transluminal Coronary Angioplasty 
        2.1.1 Approaches 
        2.1.2 Indications 
        2.1.3 Complications/Efficacy 
        2.1.4 Adjunctive Anti-Clotting Drug Therapies
        2.1.5 Conventional Angioplasty and Emerging Drug-Eluting Balloon Angioplasty 
        2.1.6 Products 
            2.1.6.1 Balloon Angioplasty Catheters 
            2.1.6.2 Guiding Catheters 
            2.1.6.3 Guidewires 
            2.1.6.4 Inflation Devices
            2.1.6.5 Introducers/Sheaths 
            2.1.6.6 Vascular Access Site Closure Devices 
        2.1.7 Procedure Volumes Forecast 
        2.1.8 Market Forecast 
        2.1.9 Competitors 

Exhibit 2-1: 2010, Selected Conventional Percutaneous Transluminal Coronary Angioplasty Balloon Catheters 
Exhibit 2-2: 2010, Selected Drug-Eluting Balloon Angioplasty Catheters 
Exhibit 2-3: 2010, Selected Guiding Catheters 
Exhibit 2-4: 2010, Selected Guidewires 
Exhibit 2-5: 2010, Selected Inflation Devices 
Exhibit 2-6: 2010, Selected Introducers/Sheaths 
Exhibit 2-7: 2010, Selected Vascular Access Site Closure Devices 
Exhibit 2-8: Percutaneous Transluminal Coronary Angioplasty/Coronary Stenting, Procedure Volumes Forecast, 2009-2014 
Exhibit 2-9: Percutaneous Transluminal Coronary Angioplasty Devices, Market Forecast, 2009-2014 
Exhibit 2-10: 2009, Percutaneous Transluminal Coronary Angioplasty Devices Market, Share by Supplier

3. CORONARY STENT SYSTEMS MARKET 
    3.1 Coronary Stenting with Bare-Metal and Drug-Eluting Stents 
        3.1.1 Stent Materials 
            3.1.1.1 Cobalt-Based Alloys 
            3.1.1.2 Nitinol 
            3.1.1.3 Stainless Steel 
            3.1.1.4 Tantalum 
            3.1.1.5 Bioabsorbable Polymers and Metal-Based Alloys 
        3.1.2 Stent Coatings/Surfaces and Anti-Restenosis Agents 
        3.1.3 Stent Delivery/Deployment 
        3.1.4 Indications 
            3.1.4.1 Left Main Coronary Artery Disease 
            3.1.4.2 Multivessel Coronary Artery Disease 
        3.1.5 Complications/Efficacy 
            3.1.5.1 Repeat Revascularization 
            3.1.5.2 Stent Thrombosis 
            3.1.5.3 Diabetes and Stenting 
            3.1.5.4 Stenting-Associated ST-Segment Elevation Myocardial Infarction 
        3.1.6 Products 
        3.1.7 Procedure Volumes Forecast 
        3.1.8 Market Forecast
        3.1.9 Competitors 

Exhibit 3-1: 2010, Selected Anti-Restenosis Agents 
Exhibit 3-2: 2010, Selected Coronary Stents 
Exhibit 3-3: Coronary Stenting, Procedure Volumes Forecast, 2009-2014
Exhibit 3-4: Coronary Stents, Market Forecast, 2009-2014
Exhibit 3-5: 2009, Coronary Stent Systems Market, Share by Supplier

4. COMPANY PROFILES1
    4.1 Abbott Laboratories 
    4.2 Boston Scientific Corporation 
    4.3 B. Braun Melsungen AG 
    4.4 Cook Group, Inc. 
    4.5 Cordis Corporation/Johnson & Johnson
    4.6 InSitu Technologies, Inc. 
    4.7 Medtronic, Inc. 
    4.8 Merit Medical Systems, Inc. 
    4.9 OrbusNeich 
    4.10 St. Jude Medical, Inc. 
    4.11 Terumo Medical Corporation/Terumo Corporation 
    4.12 Vascular Solutions, Inc. 

APPENDIX: COMPANY LISTING 


COMPANIES COVERED:

  1. Abbott Laboratories
  2. Boston Scientific Corporation
  3. B. Braun Melsungen AG
  4. Cook Group, Inc.
  5. Cordis Corporation/Johnson & Johnson
  6. InSitu Technologies, Inc.
  7. Medtronic, Inc.
  8. Merit Medical Systems, Inc.
  9. OrbusNeich
  10. St. Jude Medical, Inc.
  11. Terumo Medical Corporation/Terumo Corporation
  12. Vascular Solutions, Inc.
Contact Us

Need help finding medtech research? Let us help you!